Health care futurists believe that by 2040, most care will be delivered at home, in outpatient settings or virtually. Adapting to this new way of care — in terms of supplies and delivery methods — will require relationships with different types of vendors, such as retailers, contract employees and technology providers.
Personalised medicine. Personalised medicine tailored to the unique needs, genetic makeup and lifestyle of each patient will continue to be an important trend in healthcare. Moving past a one-size-fits-all approach could lead to fewer ineffective interventions and better outcomes.
Payers will shape their investments and plan designs to drive high-quality virtual care and increasingly recognize home as a path for care, while managing their networks for high acuity and chronic care pathways. Have we explored all the ways to grow and capture revenue?
According to a 2020 survey of health care consumers, an “ideal” health care experience requires a personal touch, whether that encounter occurs virtually or in person. Patients say it’s paramount that clinicians take time to listen, show they care and communicate clearly.
In February 2020, less than 1 percent of Medicare primary care visits were conducted via telehealth; by April, driven by the pandemic, the volume had risen to 43 percent. This growth appears to have staying power as both patients and physicians adopt a new virtualization mindset.
U.S. hospitals will exceed $320 billion in losses in 2020 due to the impact of COVID-19, according to AHA projections. Financial pressures will continue to be prevalent as more providers see a lifeline in partnering with larger organizations to remain competitive in today’s health care landscape.
Please note that the views of authors do not always reflect the views of AHA.
Immunotherapies have produced remarkable results in many, but not all, patients. The challenge of immuno-oncology is how each discovery unlocks new questions. The future fight against cancer will rest on understanding why some tumor cells may begin to resist these therapies, and developing novel treatment combinations that are based on the unique characteristics of tumors and individual patients. Finding answers to such complex quandaries requires true collaboration, which is why Pfizer is relentless in our pursuit to advance cancer therapy by cultivating the right partnerships.
But as we embrace the potential of personal health data we must also be mindful of pitfalls we might encounter on the way to a more data-driven future. Privacy, of course, is of utmost importance. While data sharing can open the door to potentially transformative conveniences and benefits for patients, in the wrong hands, data can also expose patients to unnecessary risk and discrimination.
Personalised medicine tailored to the unique needs, genetic makeup and lifestyle of each patient will continue to be an important trend in healthcare. Moving past a one-size-fits-all approach could lead to fewer ineffective interventions and better outcomes. For instance, a recent PriceWaterhouseCoopers report found that using a genetic test on breast cancer patients reduced chemotherapy use by 34%.